Prophylactic pravastatin versus pentoxifylline plus vitamin E to prevent radiation-related lymphedema and fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, registry-embedded, Bayesian randomized Phase 2 trial at a single center comparing pravastatin to pentoxifylline plus tocopherol given prophylactically to adults undergoing radiotherapy for oropharyngeal squamous carcinoma. Participants are randomized to one of the active regimens and followed longitudinally during and after radiotherapy. Primary outcomes are clinician-rated measures of radiation-induced lymphedema and fibrosis, with secondary outcomes including imaging-derived objective measures and patient-reported toxicity and function. The design uses Bayesian methods embedded within a clinical registry to estimate relative effect sizes between the two interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

• Untreated T0-T4N0-3M0 oropharyngeal squamous carcinoma.

1. Dispositioned to radiotherapy with prescribed dose to unilateral or bilateral neck(s).
2. Creatinine clearance \>30mL/min
3. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of pentoxifylline/pravastatin in participants \<18 years of age, children are excluded from this study
4. ECOG performance status ≤2 (Karnofsky ≥60%,)
5. Participants must have adequate organ and marrow function as defined below

   * absolute neutrophil count ≥1,000/mcL
   * platelets ≥100,000/mcL
   * total bilirubin ≤ institutional upper limit of normal (ULN)
   * AST(SGOT)/ALT(SGPT) ≤3 x institutional ULN
   * creatinine ≤1.5 x institutional ULN
6. The effects of pentoxifylline/pravastatin on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following.

   * Postmenopausal (no menses in greater than or equal to 12 consecutive months).
   * History of hysterectomy or bilateral salpingo-oophorectomy.
   * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
   * History of bilateral tubal ligation or another surgical sterilization procedure.
   * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
7. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism.
2. History of myopathy/rhabdomyolysis.
3. History of acute myocardial infarction or severe coronary disease.
4. Pregnant/post-menopausal, or male.
5. History of diabetes mellitus.
6. Allergy/hypersensitivity to Hydroxymethylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor and/or xanthine derivatives, e.g., caffeine, theophylline, theobromine.
7. Contraindications for MRI
8. Participants who are receiving any other investigational agents.
9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to statins, hemorheologic agents or other agents used in study
10. Participants with psychiatric illness/social situations that would limit compliance with study requirements.

Where it's running

• MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Clifton Fuller, MD,PHD — M.D. Anderson Cancer Center
• Study coordinator: Clifton Fuller, MD,PHD
• Email: cdfuller@mdanderson.org
• Phone: (832) 817-8568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reversing radiotherapy-related fibrosis and lymphedema in head and neck cancer survivors

  This trial will test whether adding one of several drugs (pravastatin, pentoxifylline, ketoprofen, or pirfenidone) to standard care can prevent or reduce radiation-related fibrosis and lymphedema in people treated for head and neck cancer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06912763

• Use of reconstructive microsurgery to treat lymphedema

  This study tests whether reconstructive microsurgery, with or without the help of indocyanine green imaging, can help people with lymphedema feel and function better by improving lymphatic drainage.

  Recruiting Istituto Ortopedico Rizzoli · Bologna · NCT07889856

• Imaging endometriosis with a special PET tracer in adult women

  This study tests whether a PET/CT scan using [18F]AlF-FAPI-74 can help detect endometriosis lesions in women who are planning laparoscopy.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07876648

• Predicting lymphedema risk in inflammatory breast cancer patients using preoperative body impedance analysis

  This study tests whether a preoperative bioimpedance test can help identify IBC patients who are at risk for developing lymphedema.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07855627

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Boosted compression for lower limb edema

  This study tests whether applying a multicomponent short-stretch bandage three times daily (boosted compression) helps reduce edema faster in people with chronic edema or lymphedema of the legs, compared with the standard single daily bandage.

  Recruiting at 4 sites Universiteit Antwerpen · Edegem, Antwerp and 3 other locations · NCT07708662

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.